Literature DB >> 31264483

Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study.

Fatemeh Foroozanfard1, Zatollah Asemi2, Fatemeh Bazarganipour3, Seyed Abdolvahab Taghavi3, Helen Allan4, Shahintaj Aramesh5.   

Abstract

The aim of this study was to compare pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome (PCOS) with healthy women. A prospective cohort study from the beginning to the end of pregnancy for 41 pregnant women with PCOS (case) and 49 healthy pregnant women (control) was completed. Based on the presence or absence of menstrual dysfunction (M), hyperandrogenism (HA), and polycystic ovaries (PCO) on ultrasound, the PCOS (case) group were divided into three phenotypes (HA + PCO (n = 22), M + PCO (n = 9), HA + M+PCO (n = 10). Pre-eclampsia, gestational diabetes, and lower birth weight among newborns were significantly higher in the PCOS case group compared to the control group especially in the phenotype HA + M+PCO (p < .05). High BMI (β = 2.40; p=.03) was the strongest predictor of pre-eclampsia in patients with PCOS. High androgen levels (free androgen index) (β = 13.71, 3.02; p < .05), was the strongest predictor of developing diabetes during pregnancy and reduced birth weight baby, respectively.These results suggest that PCOS, particularly in phenotype HA + M+PCO (p < .05), is a risk factor for adverse pregnancy and neonatal outcomes including gestational diabetes, pre-eclampsia, and reduced weight babies.

Entities:  

Keywords:  Polycystic ovary syndrome; neonatal complications; phenotype; pregnancy complications

Year:  2019        PMID: 31264483     DOI: 10.1080/09513590.2019.1631278

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

1.  A comparative study of epidural labor analgesia and natural delivery without analgesia.

Authors:  Deying Luo; Yuan Yuan; Le Guo; Zhugen Chen
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 2.  Assessment of Early Markers of Cardiovascular Risk in Polycystic Ovary Syndrome.

Authors:  Krystallenia I Alexandraki; Eleni A Kandaraki; Kalliopi-Anna Poulia; Christina Piperi; Eirini Papadimitriou; Theodoros G Papaioannou
Journal:  touchREV Endocrinol       Date:  2021-04-28

Review 3.  Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome.

Authors:  Xianqin Qu; Richard Donnelly
Journal:  Int J Mol Sci       Date:  2020-11-01       Impact factor: 5.923

4.  Association Between Menstrual Patterns and Adverse Pregnancy Outcomes in Patients With Polycystic Ovary Syndrome.

Authors:  Ting Yu; Di Wu; Yurong Cao; Jun Zhai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

Review 5.  The incidence of gestational diabetes mellitus among women with polycystic ovary syndrome: a meta-analysis of longitudinal studies.

Authors:  Qingzi Yan; Dan Qiu; Xiang Liu; Qichang Xing; Renzhu Liu; Yixiang Hu
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-29       Impact factor: 3.105

6.  An early model to predict the risk of gestational diabetes mellitus in the absence of blood examination indexes: application in primary health care centres.

Authors:  Jingyuan Wang; Bohan Lv; Xiujuan Chen; Yueshuai Pan; Kai Chen; Yan Zhang; Qianqian Li; Lili Wei; Yan Liu
Journal:  BMC Pregnancy Childbirth       Date:  2021-12-08       Impact factor: 3.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.